Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
New Publication: Headroom Approach to Device Development
23 February 2016
OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.
How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards
24 November 2015
A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.
OHE at ISPOR Latin America: Policy Options for Formulary Development in Middle-income Countries
20 October 2015
This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries,…
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are…
LSE-ICL Medical Innovation Forum on 14th October 2015: Assessing Value and Sustainable Financing of Innovative Therapies.
29 September 2015
OHE’s Adrian Towse to speak on Options for the Sustainable Financing of Innovative Therapies.
OHE Lunchtime Seminar on 6 October 2015 PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing
22 September 2015
On Tuesday 6th October, James Anderson (GSK), Ri De Ridder (RIZIV-INAMI), and Sophia Tickell (Meteosan) will take part in an OHE seminar to discuss the Checklist…
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
25 August 2015
A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE.